Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > News????
View:
Post by boazklinghorn on Nov 27, 2023 9:36am

News????

They are putting out anything they can get their hands on to avoid/obfiscate 3Q results. More studies and tests and trials that are at least several years from anything of signifcance if they in fact amount to anything at all.
Comment by prophetoffactz on Nov 27, 2023 10:10am
"More studies and tests and trials that are at least several years from anything of signifcance..." Phase I human clinical trials are significant and clinicaltrials.gov has an estimated timeline to completion of September 2024. Only 9-10 months away. Certain data read-outs could start being available very quickly given the timelines at clinicaltrials.gov for multiple metrics. Phase I ...more  
Comment by boazklinghorn on Nov 27, 2023 10:24am
Ah Proph you and Gilles deserve each other. 1) Completion of phase 1 doesnt matter at all, 2) there is no real moat for avanathranides as Symrise has recently proven.  So even if at the successful conclusion of phase 3 studies in 3 or 4 years if the results are strong any number of larger more well capitalized companies can jump in and take whatever gains there are.
Comment by boazklinghorn on Nov 27, 2023 11:01am
Hello Ceapro passengers this is Captain Gagnon from the fight deck. We have had a sudden loss of revenue power, brace for impact. As captain I have the "golden parchute" and I will safe but the rest of you may feel a bit of a CRASH. On behalf of myself and copilot Ronnie Thank you for flying Ceapro and we sincerley hope you survive". 
Comment by prophetoffactz on Nov 27, 2023 11:14am
"2) there is no real moat for avanathranides as Symrise has recently proven..." It took CZO 4 years to develop the well characterized, pharma-grade pill. From the time to develop a pill to running a human clinical trial for a pharmaceutical drug, CZO could have over a five year lead-to-market for a drug. CZO doesn't just use avenanthramide it uses selective components of ...more  
Comment by boazklinghorn on Nov 27, 2023 11:26am
Captain Gagnon again from the flight deck, As one of our two main engines is no longer working and our plane continues to lose alititude your stewardess "Proph" will be passing through the cabin offering you insurance that may or may not pay out in 5 years, if you have any interest in this product please buy more CZO stock now. Again copilot Ronnie and myself will be fine so dont worry ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities